secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001193125-25-052940
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir shareholders approve merger with Kalaris; combined co to trade as KLRS
------------------------------------------------------------------------------

- Stockholders voted to approve merger: 3,543,715 for, 368,843 against, 282 abstain out of 3,912,840 votes cast.
- 2020 Plan amended: share reserve increased by 5% of post-merger outstanding; plan term extended to 10th anniversary of closing.
- Combined company to be renamed Kalaris Therapeutics, trading on Nasdaq under ticker KLRS after closing.
- Kalaris lead candidate TH103 (anti-VEGF fusion protein) in Phase 1 trial for neovascular AMD; plans for DME and RVO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/0001193125-25-052940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/d347915d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-052940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer